In vitro activities of new macrolides and rifapentine against Brucella spp.
We have tested the in vitro activities of streptomycin, rifampin, tetracyclines, trimethoprim-sulfamethoxazole, erythromycin, four new macrolides (roxithromycin, azithromycin, clarithromycin, and dirithromycin), and rifapentine against 62 strains of Brucella spp. Azithromycin and clarithromycin were, respectively, eight- and twofold more active than erythromycins (MIC for 90% of strains = 2, 8, and 16 micrograms/ml, respectively). The activity of rifapentine was similar to that of rifampin (MIC for 90% of strains = 1 microgram/ml).
García-Rodríguez
J A
JA
Department of Microbiology, Hospital Clínico Universitario, Salamanca, Spain.
Muñoz Bellido
J L
JL
Fresnadillo
M J
MJ
Trujillano
I
I
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000995:Antitubercular Agents / Q000494:pharmacology*; D002002:Brucella / Q000187:drug effects*; D004352:Drug Resistance, Microbial; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D012293:Rifampin / Q000031:analogs & derivatives* / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D018942:Macrolides; D012293:Rifampin; C018421:rifapentine